These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500 [No Abstract] [Full Text] [Related]
6. The role of immunotherapy in small cell lung cancer. Calles A; Aguado G; Sandoval C; Álvarez R Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710 [TBL] [Abstract][Full Text] [Related]
7. Optimal drugs for second-line treatment of patients with small-cell lung cancer. Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692 [TBL] [Abstract][Full Text] [Related]
8. Prospects of targeted and immune therapies in SCLC. Hendriks LEL; Menis J; Reck M Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971 [No Abstract] [Full Text] [Related]
9. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
10. Progress and challenges in the treatment of small cell lung cancer. Tartarone A; Giordano P; Lerose R; Rodriquenz MG; Conca R; Aieta M Med Oncol; 2017 Jun; 34(6):110. PubMed ID: 28456992 [TBL] [Abstract][Full Text] [Related]
11. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. Spigel DR; Socinski MA J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044 [TBL] [Abstract][Full Text] [Related]
12. Treatment advances in small cell lung cancer (SCLC). Waqar SN; Morgensztern D Pharmacol Ther; 2017 Dec; 180():16-23. PubMed ID: 28579387 [TBL] [Abstract][Full Text] [Related]
13. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer. Yu L; Lai Q; Gou L; Feng J; Yang J J Drug Target; 2021 Jan; 29(1):1-11. PubMed ID: 32700566 [TBL] [Abstract][Full Text] [Related]
14. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer. Cooper MR; Alrajhi AM; Durand CR Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737 [TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors. Reddy HG; Qin A; Kalemkerian GP Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991 [TBL] [Abstract][Full Text] [Related]
16. SCLC-State of the Art and What Does the Future Have in Store? Kahnert K; Kauffmann-Guerrero D; Huber RM Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481 [TBL] [Abstract][Full Text] [Related]
17. A new hope: the immunotherapy in small cell lung cancer. Li Q; Yuan D; Ma C; Liu Y; Ma L; Lv T; Song Y Neoplasma; 2016; 63(3):342-50. PubMed ID: 26925794 [TBL] [Abstract][Full Text] [Related]
18. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Horn L; Reck M; Spigel DR Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668 [TBL] [Abstract][Full Text] [Related]
19. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727 [TBL] [Abstract][Full Text] [Related]
20. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Demedts IK; Vermaelen KY; van Meerbeeck JP Eur Respir J; 2010 Jan; 35(1):202-15. PubMed ID: 20044461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]